… to standard ATT could be an important strategy to treat this category of patients. In the … of
Mycobacterium w, renamed as Mycobacterium indicus pranii (MIP) in Cat II Pulmonary TB (Cat II …

… seek to understand the efficacy, safety, and practical applications … A pooled analysis of two
randomized controlled trials … Based on our findings, MIP is a promising adjunctive therapy for …

… To ascertain the effectiveness of MIP for enhancing clinical … to have sepsis receiving
mycobacteria indicus pranii, and … The Cochran Q test and the I 2 statistic were used to evaluate …

… Clinical trials have evaluated the efficacy of MIP in a … MIP has been found to be a potent
adjuvant. [ 44 ] This can prove to … The safety profile and affordable cost are two conducive factors …

… MIP-treatment in M.tb-infected guinea pigs. Protection with MIP-treatment was associated …
with the antibodies for macrophages and MHC class II, as per the instruction manual provided …

… to MDT in clinical Phase-II trials. In these studies no adverse … On the basis of the data on
tuberculosis protection in this … Protective efficacy of Mycobacterium indicus pranii against …

… The study is a randomized, blinded, two-arm, active comparator-controlled clinical trial for
evaluating the safety and efficacy of Mw (0.3 ml suspension delivered via the intradermal route …

… the efficacy and safety of adjunctive prednisolone and M. … We used a 2-by-2 factorial
design to independently evaluate … In conclusion, adjunctive therapy with prednisolone for 6 …

Intralesional immunotherapy with killed <i>Mycobacterium indicus</i> pranii vaccine for the
treatment of extensive cutaneous warts - Indian Journal of Dermatology, Venereology and …

… of patients were compared in two treatment arms, we could … repurposed, and the safety and
efficacy of these drugs are yet … MIP, as an adjuvant to standard therapy against tuberculosis, …